Combivent Articles
Boehringer Ingelheim’s Combivent Respimat Inhalation Spray OKed in USA to replace aerosol
9 October 2011
Merck KGaA 2nd-qtr as expected
1 August 2005
BI hit by costs and currencies in first half
11 August 2003
Strong 4th-quarter operating results at Merck KGaA on flat sales
24 February 2003
New Spiriva data reinforce profile of potential COPD blockbuster
26 September 2001
Global pulmonary drug delivery market forecasts
24 September 2001
Combivent Attack: Boeh Ingelheim Replies
5 November 1998
Poor Rxing "Costs UK NHS L100 Mill/Year In England"
28 October 1998
Sales Well Up And Solid Growth At Boehringer Ingelheim
26 August 1997
Boeh Ingelheim To Focus On Alliances
20 May 1996
UK Prescription Medicine Code Of Practice Review
4 December 1995
USA Lags Foreign Approvals, PhRMA Demonstrates
16 October 1995
Boeh Ing launches Combivent UDV
3 July 1995
B-I Receives Two Approval Recommendations In USA
25 July 1994
BOEHRINGER INGELHEIM RECEIVES NOT APPROVABLE LETTER
14 March 1994
BOEHRINGER INGELHEIM GETS GO-AHEAD FOR US TRIALS
19 July 1993
Showing 1-26 of 26 articles
- 1
- Is failure to adopt business process management putting the pharma industry at risk?
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
